Gilead Sciences’ Zydelig receives EU marketing authorization for CLL & follicular lymphoma treatments
The European Commission has granted marketing authorization for Gilead Sciences’ Zydelig (idelalisib), 150 mg tablets, a first-in-class oral treatment for […]